The Epidemiology of Hyperprolactinemia in A Single Tertiary Care Center: The Importance of Drug History and Role of An Endocrinologist

Year 2021, , 92 - 98, 25.06.2020

Mahmut Bakır Koyuncu , Kerem Sezer Gülhan Temel

https://doi.org/10.5455/umj.20210325075502

Abstract

Introduction: The underlying causes of hyperprolactinemia differ between studies. The study aimed to determine the causes, initial signs, and treatment methods of hyperprolactinemia.
Materials and Methods: Prolactin (PRL) measurement was requested from 16241 patients between January 2016
and December 2019. A total of 176 patients whose serum prolactin levels above 29.9 ng/mL in two consecutive measurements were included in this study. Electronic Health Records (EHR) of these patients were reviewed.
Results: Forty-Seven (26.8%) of 176 patients had a prolactinoma. Among the prolactinoma group, 63.8% of the patients had microadenoma. Polycystic Ovary Syndrome (PCOS)(29.5%), drugs (20.9%), and pituitary disorders other than prolactinoma (13.2%) were the most common causes of hyperprolactinemia in the non-prolactinoma group. Galactorrhea (38.3%) was the most common initial sign. Cabergoline's starting dose in the Endocrinology clinic was 1 mg/week, and 87.2% of the cases started with a 1 mg/week dose. All of the other cases (12.8%) who were diagnosed by other departments received inappropriate doses of cabergoline.
Conclusions: Drug-induced hyperprolactinemia may be much more common than previously thought. Referring these patients to the Endocrinology clinic will be much more beneficial to determine both the correct dosage of cabergoline and the cause of hyperprolactinemia.

Keywords

Hyperprolactinemia, prolactinoma, cabergoline

References

• 1. Özcan-Ekşi EE, Ekşi M, Akçal MA. Severe Lumbar Intervertebral Disc Degeneration Is Associated with Modic Changes and Fatty Infiltration in the Paraspinal Muscles at all Lumbar Levels, Except for L1-L2: A Cross-Sectional Analysis of 50 Symptomatic Women and 50 Age-Matched Symptomatic Men. World neurosurgery. 2019;122:e1069-e77
• 2.Verheijen E, Munts AG, van Haagen O, de Vries D, Dekkers O, van den Hout W, et al. Transforaminal epidural injection versus continued conservative care in acute sciatica (TEIAS trial): study protocol for a randomized controlled trial. BMC neurology. 2019;19(1):216
• 3.Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002;20(4):365-74
• 4.Cortet-Rudelli C, Sapin R, Bonneville JF, Brue T. Etiological diagnosis of hyperprolactinemia. Ann Endocrinol (Paris). 2007;68(2-3):98-105
• 5.Soto-Pedre E, Newey PJ, Bevan JS, Greig N, Leese GP. The epidemiology of hyperprolactinaemia over 20 years in the Tayside region of Scotland: the Prolactin Epidemiology, Audit and Research Study (PROLEARS). Clin Endocrinol (Oxf). 2017;86(1):60-7
• 6.Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyper prolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88
• 7. Lee DY, Oh YK, Yoon BK, Choi D. Prevalence of hyperprolactinemia in adolescents and young women with menstruation-related problems. Am J Obstet Gynecol. 2012; 206(3):213.e1-5
• 8.Mancini T, Casanueva FF, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008; 37(1):67-99
• 9.Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84(1):181-5
• 10.Carter JN, Tyson JE, Tolis G, Van Vliet S, Faiman C, Friesen HG. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med. 1978;299(16):847-52
• 11. Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperpro lactinemia: effects on fertility. Fertil Steril. 1979;32(5):556-61
• 12.Işik AZ, Gülekli B, Zorlu CG, Ergin T, Gökmen O. Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol Obstet Invest. 1997;43(3):183-5
• 13.Duignan NM. Polycystic ovarian disease. Br J Obstet Gynaecol. 1976;83(8):593-602
• 14.Corenblum B, Taylor PJ. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil Steril. 1982;38(5):549-52
• 15.Delcour C, Robin G, Young J, Dewailly D. PCOS, and Hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Health. 2019;13:1179558119871921
• 16.Ashton AK, Longdon MC. Hyperprolactinemia and galactorrhea induced by serotonin and norepinephrine reuptake inhibiting antidepressants. Am J Psychiatry. 2007; 164(7):1121-2
• 17. Yang MS, Cheng WJ, Huang MC. Dose-related hyper prolactinemia induced by venlafaxine. Prog Neuropsycho pharmacol Biol Psychiatry. 2009;33(4):733-4
• 18.Vilar L, Freitas MC, Naves LA, Casulari LA, Azevedo M, Montenegro R, Jr., et al. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. J Endocrinol Invest. 2008;31(5):436-44
• 19.Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86(11):5256-61
• 20.Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab. 2008;93(12):4721-7
• 21.Pascal-Vigneron V, Weryha G, Bosc M, Leclere J. Hyper prolactinemic amenorrhea: treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study. Presse Med. 1995;24(16): 753-7
• 22.Khare S, Lila AR, Patil R, Phadke M, Kerkar P, Bandgar T, et al. Long-term cardiac (valvulopathy) safety of cabergoline in prolactinoma. Indian J Endocrinol Metab. 2017;21(1):154-9
• 23.Colao A, Annunziato L, Lombardi G. Treatment of prolactinomas. Ann Med. 1998;30(5):452-9
• 24.Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89(4):1704-11
• 25.Ciccarelli E, Camanni F. Diagnosis and drug therapy of prolactinoma. Drugs. 1996;51(6):954-65
• 26.Webster J. Cabergoline and quinagolide therapy for prolactinomas. Clin Endocrinol (Oxf). 2000;53(5):549